Novo Nordisk (NVO.N): The company expects the adverse impact on sales in 2026 to be at the lower end of the 0%-10% range. It is expected to release its 2026 earnings guidance on February 4th.
2025-11-07
Novo Nordisk (NVO.N): The company expects the adverse impact on sales in 2026 to be at the lower end of the 0%-10% range. It is expected to release its 2026 earnings guidance on February 4th.